ABOUT ABBV-744 IN CLINICAL TRIALS FOR NON-SMALL CELL LUNG CANCER (NSCLC)

The existing work examined the potential of using ARV-825 and ABBV-744 to enhance the effectiveness of tamoxifen or fulvestrant furthermore palbociclib. ARV-825 was effective in both equally p53 wild-type (WT) breast tumor cells and in cells lacking practical p53 either alone or in combination with tamoxifen, while the effectiveness of ABBV-744 was